Compare Global X Copper Miners ETF (COPX) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Cytokinetics Inc — how do they compare? Global X Copper Miners ETF trades at $85.76 (market cap $7.10B), while Cytokinetics Inc trades at $62.69 (market cap $8.62B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Global X Copper Miners ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Copper Miners ETF for 51 Days and Cytokinetics Inc for 19 Days on average.
| COPX | CYTK | |
|---|---|---|
Market Cap | $7.10B | $8.62B |
Volume | 2,871,128 | 2,594,626 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $96.45 | $87.26 |
52-Week Low | $57.43 | $54.76 |
Typical Hold Time | 51 Days | 19 Days |
Enterprise Value | — | $8.72B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX trades at $85.85, up 2.72% today, but faces bearish technical signals with 17 sell indicators versus 2 buy signals. The ETF remains in a downtrend with key resistance at $85 and support at $79. Recent news highlights copper's critical role in AI infrastructure and electrification trends, though technical weakness persists despite positive copper price momentum.
The copper shortage narrative supports long-term fundamentals, but COPX's technical weakness and global surplus projections create near-term headwinds. Investment opportunity exists in copper's structural demand growth, balanced against mining equity underperformance relative to copper prices and Federal Reserve policy sensitivity.
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
